Of note, the scope of CDK4/6-based therapy goes beyond targeting the tumour compartment as it exerts a critical function on the TME by promoting metabolic reprogramming and tumour immunity, which might improve the efficacy of metabolic therapy or immune checkpoint blockade. The gene discussed is CDK4; the disease is neoplasm.